{"id": "HPRD50.d2.s3_HPRD50.d2.s3.p1", "text": "Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "text_with_entity_marker": "Previously, we showed that the [E1]CG beta[/E1] or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, [E2]CG beta alpha[/E2] and F beta alpha, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[31, 38]], "entity_1_idx_in_text_with_entity_marker": [35, 42], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "CG beta alpha", "entity_2_idx": [[154, 167]], "entity_2_idx_in_text_with_entity_marker": [167, 180], "entity_2_type": "pm0125097", "entity_2_type_id": 8}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s0_HPRD50.d10.s0.p1", "text": "Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1)", "text_with_entity_marker": "Cutting edge: [E1]CD43[/E1] functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin ([E2]Siglec-1[/E2])", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD43", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "Siglec-1", "entity_2_idx": [[108, 116]], "entity_2_idx_in_text_with_entity_marker": [121, 129], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s1_HPRD50.d10.s1.p2", "text": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins CD43 and P-selectin glycoprotein ligand 1 (CD162), respectively", "text_with_entity_marker": "The 130- and 240-kDa sialoadhesin-binding glycoproteins were identified as the sialomucins CD43 and [E1]P-selectin glycoprotein ligand 1[/E1] ([E2]CD162[/E2]), respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "P-selectin glycoprotein ligand 1", "entity_1_idx": [[100, 132]], "entity_1_idx_in_text_with_entity_marker": [104, 136], "entity_1_type": "pm0119091", "entity_1_type_id": 38, "entity_2": "CD162", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "pm0119091", "entity_2_type_id": 38}], "directed": false, "reverse": false}
{"id": "HPRD50.d11.s0_HPRD50.d11.s0.p2", "text": "Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 cells", "text_with_entity_marker": "Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of [E1]p85alpha[/E1] activates [E2]phosphatidylinositol 3-kinase[/E2] in C2C12 cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p85alpha", "entity_1_idx": [[92, 100]], "entity_1_idx_in_text_with_entity_marker": [96, 104], "entity_1_type": "pm0124741", "entity_1_type_id": 40, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[111, 140]], "entity_2_idx_in_text_with_entity_marker": [124, 153], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s1_HPRD50.d15.s1.p0", "text": "To clarify the mechanisms by which GPI-80 functions on leukocytes, we explored the possibility of its physical association with beta 2 integrin which is important for leukocyte adherence, locomotion, and extravasation", "text_with_entity_marker": "To clarify the mechanisms by which [E1]GPI-80[/E1] functions on leukocytes, we explored the possibility of its physical association with [E2]beta 2 integrin[/E2] which is important for leukocyte adherence, locomotion, and extravasation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-80", "entity_1_idx": [[35, 41]], "entity_1_idx_in_text_with_entity_marker": [39, 45], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "beta 2 integrin", "entity_2_idx": [[128, 143]], "entity_2_idx_in_text_with_entity_marker": [141, 156], "entity_2_type": "pm0114514", "entity_2_type_id": 48}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s2_HPRD50.d15.s2.p0", "text": "beta 2 integrin, detected by anti-CD18 mAb, was coprecipitated with GPI-80 from human neutrophil lysates by a mAb to GPI-80", "text_with_entity_marker": "[E1]beta 2 integrin[/E1], detected by anti-CD18 mAb, was coprecipitated with [E2]GPI-80[/E2] from human neutrophil lysates by a mAb to GPI-80", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "beta 2 integrin", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "pm0114514", "entity_1_type_id": 48, "entity_2": "GPI-80", "entity_2_idx": [[68, 74]], "entity_2_idx_in_text_with_entity_marker": [81, 87], "entity_2_type": "pm0100260", "entity_2_type_id": 49}], "directed": false, "reverse": false}
{"id": "HPRD50.d15.s4_HPRD50.d15.s4.p0", "text": "These results clearly show that GPI-80 is physically associated with beta 2 integrin in human neutrophils", "text_with_entity_marker": "These results clearly show that [E1]GPI-80[/E1] is physically associated with [E2]beta 2 integrin[/E2] in human neutrophils", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-80", "entity_1_idx": [[32, 38]], "entity_1_idx_in_text_with_entity_marker": [36, 42], "entity_1_type": "pm0100260", "entity_1_type_id": 49, "entity_2": "beta 2 integrin", "entity_2_idx": [[69, 84]], "entity_2_idx_in_text_with_entity_marker": [82, 97], "entity_2_type": "pm0114514", "entity_2_type_id": 48}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p6", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a ([E1]Gadd45[/E1]), Gadd45b ([E2]MyD118[/E2]), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "MyD118", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p7", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a ([E1]Gadd45[/E1]), Gadd45b (MyD118), and [E2]Gadd45g[/E2] (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45g", "entity_2_idx": [[40, 47]], "entity_2_idx_in_text_with_entity_marker": [53, 60], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p1", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that [E1]Gadd45b[/E1] and Gadd45g, as well as [E2]GADD45a[/E2], interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "GADD45a", "entity_2_idx": [[65, 72]], "entity_2_idx_in_text_with_entity_marker": [78, 85], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p7", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and Gadd45g, as well as [E1]GADD45a[/E1], interact with both [E2]Cdk1[/E2] and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45a", "entity_1_idx": [[65, 72]], "entity_1_idx_in_text_with_entity_marker": [69, 76], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Cdk1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p9", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both [E1]Cdk1[/E1] and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk1", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p2", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of [E1]Cdk1[/E1]/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas [E2]Gadd45g[/E2] did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Cdk1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Gadd45g", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p5", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and [E1]Gadd45a[/E1] was found to involve disruption of the complex, whereas [E2]Gadd45g[/E2] did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[59, 66]], "entity_1_idx_in_text_with_entity_marker": [63, 70], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "Gadd45g", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s0_HPRD50.d18.s0.p1", "text": "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)", "text_with_entity_marker": "The transmembrane [E1]receptor protein tyrosine phosphatase[/E1] DEP1 interacts with [E2]p120(ctn)[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "receptor protein tyrosine phosphatase", "entity_1_idx": [[18, 55]], "entity_1_idx_in_text_with_entity_marker": [22, 59], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "p120(ctn)", "entity_2_idx": [[76, 85]], "entity_2_idx_in_text_with_entity_marker": [89, 98], "entity_2_type": "pm0101886", "entity_2_type_id": 60}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s4_HPRD50.d18.s4.p2", "text": "Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEP1 with these proteins is specific", "text_with_entity_marker": "Catalytic domains of the tyrosine phosphatases PTP-PEST, [E1]CD45[/E1], and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of [E2]DEP1[/E2] with these proteins is specific", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD45", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "pm0110536", "entity_1_type_id": 64, "entity_2": "DEP1", "entity_2_idx": [[185, 189]], "entity_2_idx_in_text_with_entity_marker": [198, 202], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p2", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse [E1]Imp3[/E1] can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of [E2]Imp3[/E2] in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Imp3", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp3", "entity_2_idx": [[202, 206]], "entity_2_idx_in_text_with_entity_marker": [215, 219], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s2_HPRD50.d21.s2.p0", "text": "In addition, electron microscopy experiments revealed that CB1 and OX1R are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers", "text_with_entity_marker": "In addition, electron microscopy experiments revealed that [E1]CB1[/E1] and [E2]OX1R[/E2] are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CB1", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "OX1R", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p0", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "[E1]GC-GAP[/E1], a Rho family [E2]GTPase-activating protein[/E2] that interacts with signaling adapters Gab1 and Gab2", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GC-GAP", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "GTPase-activating protein", "entity_2_idx": [[21, 46]], "entity_2_idx_in_text_with_entity_marker": [34, 59], "entity_2_type": "pm0112603", "entity_2_type_id": 74}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p3", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "GC-GAP, a Rho family [E1]GTPase-activating protein[/E1] that interacts with signaling adapters [E2]Gab1[/E2] and Gab2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GTPase-activating protein", "entity_1_idx": [[21, 46]], "entity_1_idx_in_text_with_entity_marker": [25, 50], "entity_1_type": "pm0112603", "entity_1_type_id": 74, "entity_2": "Gab1", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "pm0112697", "entity_2_type_id": 75}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p8", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as [E1]Grb2[/E1], Shp-2, [E2]phosphatidylinositol 3-kinase[/E2], Shc, and Crk", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[153, 157]], "entity_1_idx_in_text_with_entity_marker": [157, 161], "entity_1_type": "pm0105419", "entity_1_type_id": 77, "entity_2": "phosphatidylinositol 3-kinase", "entity_2_idx": [[166, 195]], "entity_2_idx_in_text_with_entity_marker": [179, 208], "entity_2_type": "pm0104655||pm0110290||pm0120114||pm0122783||pm0124741", "entity_2_type_id": 12}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p1", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that [E1]Gab1[/E1] and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of [E2]GC-GAP[/E2] under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "GC-GAP", "entity_2_idx": [[118, 124]], "entity_2_idx_in_text_with_entity_marker": [131, 137], "entity_2_type": "pm0122639", "entity_2_type_id": 73}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p4", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that Gab1 and [E1]Gab2[/E1] in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and [E2]Cdc42[/E2] activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "Cdc42", "entity_2_idx": [[186, 191]], "entity_2_idx_in_text_with_entity_marker": [199, 204], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s5_HPRD50.d22.s5.p1", "text": "The GAP domain shows high similarity to the recently cloned CdGAP and displays activity toward RhoA, Rac1, and Cdc42 in vitro", "text_with_entity_marker": "The GAP domain shows high similarity to the recently cloned [E1]CdGAP[/E1] and displays activity toward RhoA, Rac1, and [E2]Cdc42[/E2] in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CdGAP", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "pm0102116", "entity_1_type_id": 82, "entity_2": "Cdc42", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p0", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and [E2]NudC[/E2], show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p3", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type [E1]NudC[/E1], but not by [E2]NudC[/E2] with mutations in the Plk1 phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[200, 204]], "entity_1_idx_in_text_with_entity_marker": [204, 208], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[217, 221]], "entity_2_idx_in_text_with_entity_marker": [230, 234], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s1_HPRD50.d25.s1.p2", "text": "BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "text_with_entity_marker": "BACKGROUND: Both androgen receptor (AR) and orphan receptor [E1]TR2[/E1] ([E2]TR2[/E2]) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "TR2", "entity_2_idx": [[65, 68]], "entity_2_idx_in_text_with_entity_marker": [78, 81], "entity_2_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_2_type_id": 90}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s2_HPRD50.d25.s2.p1", "text": "The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay", "text_with_entity_marker": "The interaction between AR and [E1]TR2[/E1] was assessed by glutathione-S-transferase ([E2]GST[/E2]) pull-down assay and mammalian two-hybrid system assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "GST", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s1_HPRD50.d26.s1.p0", "text": "We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome", "text_with_entity_marker": "We establish that [E1]pVHL[/E1] binds to [E2]Tat-binding protein-1[/E2] (TBP-1), a component of the 19S regulatory complex of the proteasome", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Tat-binding protein-1", "entity_2_idx": [[32, 53]], "entity_2_idx_in_text_with_entity_marker": [45, 66], "entity_2_type": "pm0113245", "entity_2_type_id": 94}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s1_HPRD50.d26.s1.p2", "text": "We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome", "text_with_entity_marker": "We establish that pVHL binds to [E1]Tat-binding protein-1[/E1] ([E2]TBP-1[/E2]), a component of the 19S regulatory complex of the proteasome", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Tat-binding protein-1", "entity_1_idx": [[32, 53]], "entity_1_idx_in_text_with_entity_marker": [36, 57], "entity_1_type": "pm0113245", "entity_1_type_id": 94, "entity_2": "TBP-1", "entity_2_idx": [[55, 60]], "entity_2_idx_in_text_with_entity_marker": [68, 73], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p1", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "[E1]TBP-1[/E1] associates with the beta-domain of pVHL and complexes with [E2]pVHL[/E2] and Hif1 alpha in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "pVHL", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s5_HPRD50.d26.s5.p1", "text": "Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1", "text_with_entity_marker": "Several distinct mutations in exon 2 of [E1]VHL[/E1] disrupt binding of pVHL to [E2]TBP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "VHL", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "TBP-1", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s1_HPRD50.d27.s1.p0", "text": "Three SR-rich proteins were identified that interact with the C-terminus of Pnn: SRp75 and SRm300, known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130", "text_with_entity_marker": "Three SR-rich proteins were identified that interact with the C-terminus of Pnn: [E1]SRp75[/E1] and [E2]SRm300[/E2], known components of spliceosome machinery, and a novel 130-kDa nuclear protein, SRrp130", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRp75", "entity_1_idx": [[81, 86]], "entity_1_idx_in_text_with_entity_marker": [85, 90], "entity_1_type": "pm0111657", "entity_1_type_id": 97, "entity_2": "SRm300", "entity_2_idx": [[91, 97]], "entity_2_idx_in_text_with_entity_marker": [104, 110], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s1_HPRD50.d28.s1.p0", "text": "We found that phosphorylation of Chk1 by ATR also requires checkpoint proteins Rad17 and replication protein A", "text_with_entity_marker": "We found that phosphorylation of [E1]Chk1[/E1] by ATR also requires checkpoint proteins [E2]Rad17[/E2] and replication protein A", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Chk1", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "pm0113524", "entity_1_type_id": 100, "entity_2": "Rad17", "entity_2_idx": [[79, 84]], "entity_2_idx_in_text_with_entity_marker": [92, 97], "entity_2_type": "pm0117336", "entity_2_type_id": 102}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p6", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E1]Ubc9[/E1] and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Ubc9", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "pm0110323", "entity_1_type_id": 105, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p2", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E2]decorin[/E2] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "decorin", "entity_2_idx": [[111, 118]], "entity_2_idx_in_text_with_entity_marker": [124, 131], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p7", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E2]decorin[/E2] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "decorin", "entity_2_idx": [[111, 118]], "entity_2_idx_in_text_with_entity_marker": [124, 131], "entity_2_type": "pm0108608", "entity_2_type_id": 116}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p9", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d34.s0_HPRD50.d34.s0.p0", "text": "The human apoB mRNA editing protein is a cytidine deaminase showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases", "text_with_entity_marker": "The human [E1]apoB[/E1] mRNA editing protein is a [E2]cytidine deaminase[/E2] showing structural homology to some known mammalian and bacteriophage deoxycytidylate deaminases", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "apoB", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0126272", "entity_1_type_id": 130, "entity_2": "cytidine deaminase", "entity_2_idx": [[41, 59]], "entity_2_idx_in_text_with_entity_marker": [54, 72], "entity_2_type": "pm0107865", "entity_2_type_id": 131}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s3_HPRD50.d36.s3.p0", "text": "Complexes of either CD22/PTP-1C/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively", "text_with_entity_marker": "Complexes of either [E1]CD22[/E1]/[E2]PTP-1C[/E2]/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[25, 31]], "entity_2_idx_in_text_with_entity_marker": [38, 44], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p10", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E1]desmoplakin[/E1], elafin, keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[187, 198]], "entity_1_idx_in_text_with_entity_marker": [191, 202], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s1_HPRD50.d38.s1.p2", "text": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "text_with_entity_marker": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to [E1]desmoplakin[/E1], glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain [E2]involucrin[/E2] cross-links", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[127, 138]], "entity_1_idx_in_text_with_entity_marker": [131, 142], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "involucrin", "entity_2_idx": [[239, 249]], "entity_2_idx_in_text_with_entity_marker": [252, 262], "entity_2_type": "pm0104308", "entity_2_type_id": 139}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s4_HPRD50.d42.s4.p0", "text": "Accordingly, Bcl3 coactivated the 9-cis-RA-induced transactivations of RXR, in contrast to the inhibitory actions of IkappaBbeta", "text_with_entity_marker": "Accordingly, [E1]Bcl3[/E1] coactivated the 9-cis-RA-induced transactivations of RXR, in contrast to the inhibitory actions of [E2]IkappaBbeta[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl3", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "IkappaBbeta", "entity_2_idx": [[117, 128]], "entity_2_idx_in_text_with_entity_marker": [130, 141], "entity_2_type": "pm0122183", "entity_2_type_id": 152}], "directed": false, "reverse": false}
